Current concepts in the treatment of panic disorder

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 18, 1999, Pages 16-21

  Sheehan, David V ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; LOFEPRAMINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PHENELZINE; RITANSERIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; PANIC; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; TREATMENT PLANNING;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZODIAZEPINES; CLINICAL TRIALS; FLUOXETINE; FLUVOXAMINE; HUMANS; META-ANALYSIS; MONOAMINE OXIDASE INHIBITORS; PANIC DISORDER; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME;

EID: 0032875391     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kassler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19
2. Weissman MM, Bland RC, Canino GJ, et al. The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 1997;54:305-309
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
4. Fleet RP, Dupuis G, Marchand A, et al. Panic disorder in emergency department chest pain patients: prevalence, comorbidity, suicidal ideation, and physician recognition. Am J Med 1996;101:371-380
5. Hirschfeld RMA. Panic disorder: diagnosis, epidemiology, and clinical course. J Clin Psychiatry 1996;57(suppl 10):3-8
6. Lecrubier Y. Impact of comorbidity on the treatment of panic disorder. J Clin Psychiatry 1998;59(suppl 8):11-14
7. Gorman JM, Coplan JD. Comorbidity of depression and panic disorder. J Clin Psychiatry 1996;57(suppl 10):34-41
8. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998;59(suppl 8):47-54
9. Markowitz JS, Weissman MM, Oullette R, et al. Quality of life in panic disorder. Arch Gen Psychiatry 1989;46:984-992
10. Panic disorder: a treatment update [ACADEMIC HIGHLIGHTS]. J Clin Psychiatry 1997;58:36-42
11. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Panic Disorder. Am J Psychiatry 1998;155(suppl 5):1-34
12. Sheehan DV, Uzogara E, Coleman JH, et al. The treatment of panic attacks with agoraphobia with alprazolam and ibuprofen: a controlled study [abstract]. Presented at the American Psychiatric Association annual meeting; 1982; Toronto, Ontario, Canada
13. Gorman JM. The use of newer antidepressants for panic disorder. J Clin Psychiatry 1997;58(suppl 14):54-58
14. Klein DF. Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry 1967;16:118-126
15. Sheehan DV, Ballenger JC, Jacobson G. Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch Gen Psychiatry 1980;37:51-59
16. Modigh K, Westenberg HG, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992;12:251-261
17. Woodman CL, Noyes R Jr. Panic disorder: treatment with valproate. J Clin Psychiatry 1994;55:134-136
18. den Boer JA, Wesienberg HG. Serotonin function in panic disorder: a double-blind, placebo-controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) 1990;102:85-94
19. Black DW, Wesner R, Bowers W, et al. A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44-50
20. De Beurs E, van Balkom AJLM, Lange A, et al. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry 1995;152:683-691
21. den Boer JA, Westenberg HGM, Kamerbeck WE, et al. Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987;2:21-32
22. Hoehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic-disorder. J Clin Psychopharmacol 1993;13:321-326
23. Gorman JM, Liebowitz MR, Fryer AJ. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987;7:329-332
24. Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993;54:435-438
25. Pecknold JC, Luthe L, Iny L, et al. Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study. J Psychiatry Neurosci 1995;20:193-198
26. Schneier F, Liebowitz MR, Davies SO, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990;10:119-121
27. Baumel B. Double-blind comparison of sertraline and placebo in patients with panic disorder [poster]. Presented at the 20th Collegium International Neuro-Psychopharmacologicum (CINP); June 23-27, 1996; Melbourne, Australia
28. Du Boff E, England D, Ferguson JM. Sertraline in the treatment of panic-disorder [abstract]. Presented at the 8th Congress of the European College of Neuropsychopharmacology; Sept 30-Oct 4, 1995; Venice, Italy
29. Gorman J, Wolkow R. Sertraline as a treatment for panic disorder. Neuropsychopharmacology 1994;10(35 pt 2):1975
30. Pollack M. Double blind, flexible dose comparison of sertraline and placebo in outpatients with panic disorder [poster]. Presented at the 35th annual meeting of the American College of Neuropsychopharmacology; Dec 9-13, 1996; San Juan, Puerto Rico
31. Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic-disorder: a double-blind multicenter trial. Am J Psychiatry 1998;155: 1189-1195
32. den Boer JA. Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint. J Clin Psychiatry 1998;59(suppl 8):30-36
33. Lecrubier Y, Bakker A, Dunbar G, et al. Collaborative Paroxetine Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand 1997;95:145-152
34. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatr Scand 1997;95:153-160
35. Ballenger JC, Wheadon DE, Steiner MX, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998;155:36-42
36. Burnham DB, Steiner MX, Gergel IP, et al. Paroxetine long-term safety and efficacy in panic disorder and prevention of relapse: a double-blind study. In: American College of Neuropsychophamarcology 34th Annual Meeting Scientific Abstracts; Dec 11-14, 1995; San Juan, Puerto Rico: 201
37. Oehrberg S, Christiansen PE, Behnke K. Paroxetine in the treatment of panic disorder: a randomized, double-blind, placebo-controlled study. Br J Psychiatry 1995;167:374-379
38. Dassylva B, Fontaine R, Gammans D, et al. Efficacy of nefazodone in patients suffering from major depressive disorder and panic disorder. Biol Psychiatry 1992;31:169A
39. Humble M, Wistedt B. Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders. Int Clin Psychopharmacol 1992;6(suppl 5):21-39
40. Pollack MH, Worthington JJ 3rd, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996;32:667-670
41. Wade AG, Lepola U, Koponen HJ, et al. The effect of citalopram in panic-disorder. Br J Psychiatry 1997;170:549-553
42. Boyer W. Serotonin uptake inhibitors are superior to alprazolam and imipramine in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995;10:45-49
43. Davidson JRT. Long-term treatment of panic disorder. J Clin Psychiatry 1998;59(suppl 8):17-21